Royalty Pharma plc (RPRX)
NASDAQ: RPRX · Real-Time Price · USD
44.25
+0.04 (0.09%)
At close: Feb 11, 2026, 4:00 PM EST
44.94
+0.69 (1.56%)
After-hours: Feb 11, 2026, 7:59 PM EST
Royalty Pharma Stock Forecast
Stock Price Forecast
The 4 analysts that cover Royalty Pharma stock have a consensus rating of "Strong Buy" and an average price target of $47.75, which forecasts a 7.91% increase in the stock price over the next year. The lowest target is $42 and the highest is $54.
Price Target: $47.75 (+7.91%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Royalty Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $48 → $50 | Strong Buy | Maintains | $48 → $50 | +12.99% | Jan 27, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $42 → $45 | Strong Buy | Maintains | $42 → $45 | +1.69% | Dec 11, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $55 → $54 | Buy | Maintains | $55 → $54 | +22.03% | Oct 10, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $42 | Strong Buy | Initiates | $42 | -5.08% | Sep 30, 2025 |
| Citigroup | Citigroup | Strong Buy Maintains $40 → $42 | Strong Buy | Maintains | $40 → $42 | -5.08% | Jul 22, 2025 |
Financial Forecast
Revenue This Year
3.23B
from 2.38B
Increased by 35.70%
Revenue Next Year
3.46B
from 3.23B
Increased by 7.10%
EPS This Year
5.19
from 1.80
Increased by 188.63%
EPS Next Year
5.91
from 5.19
Increased by 14.02%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 3.6B | 3.9B | |||
| Avg | 3.2B | 3.5B | |||
| Low | 2.6B | 2.5B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 52.6% | 22.0% | |||
| Avg | 35.7% | 7.1% | |||
| Low | 7.4% | -21.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.72 | 6.97 | |||
| Avg | 5.19 | 5.91 | |||
| Low | 4.49 | 5.34 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 218.4% | 34.4% | |||
| Avg | 188.6% | 14.0% | |||
| Low | 149.8% | 3.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.